These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 3492701)
1. Differences in drug susceptibility between isolates of Pseudomonas cepacia recovered from patients with cystic fibrosis and other sources and its relationship to beta-lactamase focusing pattern. Aronoff SC; Labrozzi PH Pediatr Pulmonol; 1986; 2(6):368-72. PubMed ID: 3492701 [TBL] [Abstract][Full Text] [Related]
2. Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of Pseudomonas cepacia isolated from children with cystic fibrosis. Chiesa C; Labrozzi PH; Aronoff SC Pediatr Res; 1986 Nov; 20(11):1174-7. PubMed ID: 3540826 [TBL] [Abstract][Full Text] [Related]
3. Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Aronoff SC Antimicrob Agents Chemother; 1988 Nov; 32(11):1636-9. PubMed ID: 2855296 [TBL] [Abstract][Full Text] [Related]
4. Derepressed beta-lactamase production as a mediator of high-level beta-lactam resistance in Pseudomonas cepacia. Aronoff SC Pediatr Pulmonol; 1988; 4(2):72-7. PubMed ID: 3260021 [TBL] [Abstract][Full Text] [Related]
5. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis. Aronoff SC; Klinger JD J Antimicrob Chemother; 1985 May; 15(5):545-9. PubMed ID: 3924879 [TBL] [Abstract][Full Text] [Related]
7. Effect of pH and CO2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams. Corkill JE; Deveney J; Pratt J; Shears P; Smyth A; Heaf D; Hart CA Pediatr Res; 1994 Mar; 35(3):299-302. PubMed ID: 7514780 [TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
10. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. Giwercman B; Lambert PA; Rosdahl VT; Shand GH; Høiby N J Antimicrob Chemother; 1990 Aug; 26(2):247-59. PubMed ID: 2170321 [TBL] [Abstract][Full Text] [Related]
11. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560 [TBL] [Abstract][Full Text] [Related]
12. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Giwercman B; Meyer C; Lambert PA; Reinert C; Høiby N Antimicrob Agents Chemother; 1992 Jan; 36(1):71-6. PubMed ID: 1590704 [TBL] [Abstract][Full Text] [Related]
13. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A; J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014 [TBL] [Abstract][Full Text] [Related]
14. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains]. Aktaş Z; Satana D; Kayacan C; Can B; Gönüllü N; Küçükbasmacı O Mikrobiyol Bul; 2012 Jul; 46(3):386-97. PubMed ID: 22951651 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Traczewski MM; Brown SD Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756 [TBL] [Abstract][Full Text] [Related]
17. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams. Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925 [TBL] [Abstract][Full Text] [Related]
18. Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Sherrard LJ; McGrath SJ; McIlreavey L; Hatch J; Wolfgang MC; Muhlebach MS; Gilpin DF; Elborn JS; Tunney MM Int J Antimicrob Agents; 2016 Feb; 47(2):140-5. PubMed ID: 26774156 [TBL] [Abstract][Full Text] [Related]
19. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Cheng K; Smyth RL; Govan JR; Doherty C; Winstanley C; Denning N; Heaf DP; van Saene H; Hart CA Lancet; 1996 Sep; 348(9028):639-42. PubMed ID: 8782753 [TBL] [Abstract][Full Text] [Related]
20. Correlation between genotype and beta-lactamases of clinical and environmental strains of Stenotrophomonas maltophilia. Denton M; Keer V; Hawkey PM J Antimicrob Chemother; 1999 Apr; 43(4):555-8. PubMed ID: 10350386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]